Bellinato, Francesco http://orcid.org/0000-0002-6163-6921
Maurelli, Martina http://orcid.org/0000-0001-7492-8010
Geat, Davide
Girolomoni, Giampiero http://orcid.org/0000-0001-8548-0493
Gisondi, Paolo http://orcid.org/0000-0002-1777-9001
Funding for this research was provided by:
Horizon 2020 Framework Programme (848028)
Università degli Studi di Verona
Article History
Accepted: 14 March 2024
First Online: 15 May 2024
Declarations
:
: Open access funding provided by Università degli Studi di Verona within the CRUI-CARE Agreement. This research was supported by grants from European Union’s Horizon 2020 Research and In-novation Program (Grant agreement no. 848028).
: Martina Maurelli, Francesco Bellinato, and Davide Geat have no conflicts that are directly relevant to the content of this article. Gisondi Paolo has been a consultant and/or speaker for AbbVie, Almirall, Amgen, Janssen, LEO pharma, Eli Lilly, Novartis, Pierre Fabre, Sandoz, Sanofi, and UCB. Girolomoni Giampiero served as a consultant and/or speaker for AbbVie, Abiogen, Almirall, Amgen, Biogen, Boeringher Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Genzyme, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi, and UCB.
: Not applicable.
: Not applicable.
: Not applicable.
: Data can be made available upon request to the authors.
: Not applicable.
: MM, FB, and DG wrote the first draft of the manuscript. GP and GG made revisions to the final version of the manuscript.